Drug Profile
Camostat mesilate - Daewoong Pharmaceutical
Alternative Names: Camostat Mesylate - Daewoong Pharmaceutical; DWJ-1248; FoistarLatest Information Update: 13 Oct 2023
Price :
$50
*
At a glance
- Originator Daewoong Pharmaceutical
- Class Anti-inflammatories; Antineoplastics; Antiulcers; Antivirals; Benzene derivatives; Guanidines; Inorganic sulfur compounds; Small molecules
- Mechanism of Action Peptide hydrolase inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III COVID 2019 infections
Most Recent Events
- 27 Sep 2023 Daewoong Pharmaceutical terminates a phase III trial in COVID-2019 infections (Combination therapy, In adults, In the elderly) in South Korea (PO) (NCT04713176)
- 04 Dec 2022 Daewoong Pharmaceutical terminates a phase III trial in COVID-2019 infections (Prevention, In adults, In the elderly) in South Korea (PO, Tablet) (NCT04721535)
- 18 Mar 2022 Daewoong Pharmaceutical terminates a phase II/ III trial in COVID-2019 infection in South Korea (PO) due to changes in drug development plans (NCT04521296)